CARMAT’s artificial heart could potentially save thousands of patients without any risk of rejection. Credit: CARMAT.

French biomedical company Carmat, designer of the world’s most advanced total artificial heart project, has received approval to enrol patients for the second stage of the PIVOTAL study in Denmark.

Denmark is the third country after Kazakhstan and the Czech Republic, where the company has received the required authorisation for Phase I of the PIVOTAL study.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

After the company made changes at prosthesis manufacturing process level, it had to resubmit the clinical trial for reauthorisation in all three countries. Denmark was the first country to approve.

Carmat will continue the study with the new prostheses exclusively produced on the Bois-d’Arcy site.

The implants will be complete at the Rigshospitalet’s Department of Cardiology in Copenhagen according to the requirements stated by the ethical committee.

Carmat CEO Stéphane Piat says: “This approval in Denmark allows us to be in line with our roadmap. I firmly believe that the teams headed by Prof Finn Gustafsson, Co-Principal Investigator for the second part of the PIVOTAL study, will put all of their expertise into serving the first Danish patients who will receive our new prosthesis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Given its sturdiness and the recent positive autoregulation results, we are confident that we can meet the requirements of patients awaiting a heart transplant and those who are not eligible for a transplant.”

Piat further added that the company is in discussions with the authorities in the Czech Republic and Kazakhstan to finalise the enrolment of the second patient cohort in the PIVOTAL study.

The company also plans to submit the reports from the trial to the DEKRA certification body to attain CE marking by next year.

In July last year, Carmat successfully implanted the device in a tenth patient, completing the first part of the PIVOTAL study.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact